Fortress Biotech (FBIO) Given Daily Media Impact Rating of 0.18

Media headlines about Fortress Biotech (NASDAQ:FBIO) have trended somewhat positive on Tuesday, according to Accern Sentiment Analysis. The research group rates the sentiment of media coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Fortress Biotech earned a news impact score of 0.18 on Accern’s scale. Accern also gave news headlines about the biopharmaceutical company an impact score of 46.7197441739183 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

These are some of the headlines that may have effected Accern Sentiment Analysis’s scoring:

A number of equities research analysts have recently weighed in on the company. ValuEngine cut Fortress Biotech from a “hold” rating to a “sell” rating in a research note on Tuesday, October 3rd. HC Wainwright set a $11.00 price objective on Fortress Biotech and gave the company a “buy” rating in a research note on Thursday, August 10th. Zacks Investment Research raised Fortress Biotech from a “sell” rating to a “hold” rating in a research note on Tuesday, October 10th. Rodman & Renshaw assumed coverage on Fortress Biotech in a research note on Tuesday, July 11th. They issued a “buy” rating and a $11.00 price objective for the company. Finally, FBR & Co reaffirmed a “buy” rating on shares of Fortress Biotech in a research note on Tuesday, July 4th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $11.00.

Shares of Fortress Biotech (FBIO) traded down 0.80% during midday trading on Tuesday, hitting $3.74. The stock had a trading volume of 100,415 shares. Fortress Biotech has a 12-month low of $1.88 and a 12-month high of $5.13. The stock’s market cap is $188.97 million. The stock has a 50-day moving average price of $4.41 and a 200-day moving average price of $4.29.

TRADEMARK VIOLATION NOTICE: This report was published by Community Financial News and is the sole property of of Community Financial News. If you are viewing this report on another publication, it was stolen and reposted in violation of U.S. and international trademark and copyright legislation. The legal version of this report can be read at https://www.com-unik.info/2017/10/31/fortress-biotech-fbio-given-daily-media-impact-rating-of-0-18.html.

Fortress Biotech Company Profile

Fortress Biotech, Inc, formerly Coronado Biosciences, Inc, is a biopharmaceutical company. The Company is involved in the development of immunotherapy agents for the treatment of autoimmune diseases and cancer. Its sole product candidate is CNDO-109. The Company is also focused on acquiring, developing and commercializing pharmaceutical and biotechnology products.

Insider Buying and Selling by Quarter for Fortress Biotech (NASDAQ:FBIO)

What are top analysts saying about Fortress Biotech Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Fortress Biotech Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit